How Immunotherapy Rewires Your Immune System to Tolerate Allergens

Allergy immunotherapy works by gradually introducing your immune system to the allergens that trigger your symptoms, at doses too low to cause a full allergic reaction but sufficient to engage tolerogenic dendritic cells. This triggers induction of FOXP3+ regulatory T cells and IL-10-producing Tr1 cells that suppress the IgE-mediated allergic cascade. Over months, allergen-specific IgG4 antibodies rise 10 to 100-fold and act as blocking antibodies — competing with IgE for allergen binding and preventing mast cell activation. The immune system essentially learns to recognize the allergen as harmless rather than dangerous. Akdis and Akdis (JACI 2014) characterize this as a shift from IgE-dominated Th2-type immunity toward regulatory immunity, a change that persists years after treatment ends.

The multi-year treatment requirement reflects the biology of adaptive immune change. Early mast cell desensitization occurs within hours to weeks, providing some symptomatic relief during the first treatment season. But the durable post-treatment benefit — which persists 3 to 12 years after stopping — depends on consolidating Treg expansion, achieving 10-100-fold IgG4 accumulation, and remodeling tissue eosinophil and mast cell populations at allergic mucosae. These cellular changes take 12 to 36 months to consolidate. The GRASS trial (Scadding et al., JAMA 2017) confirmed that 2-year courses produce no sustained benefit 1 year after stopping, while 3-year courses do. Stopping early means the slower adaptive changes never fully consolidate, leaving you with temporary rather than lasting tolerance.

Both allergy shots (SCIT) and sublingual drops (SLIT) ultimately drive the same immune outcomes: FOXP3+ Treg induction, IgG4 class-switching, and suppression of mast cell reactivity. However, they engage different dendritic cell populations. SCIT allergen is captured by dermal myeloid dendritic cells in the subcutaneous tissue, which efficiently traffic to lymph nodes at relatively low allergen doses. SLIT allergen is captured by oral mucosal Langerhans-like dendritic cells that are pre-programmed toward tolerogenic cytokine production but require 50-100 times higher allergen doses to generate comparable immunologic effects. This explains why SLIT is taken daily at high doses, while SCIT injections are spaced weekly with low doses. The oral mucosal environment also has much lower mast cell density than subcutaneous tissue, which is why SLIT produces fewer systemic reactions.

Evidence suggests immunotherapy can reduce the development of new allergic sensitizations in monosensitized patients, though most positive data come from non-randomized studies. Des Roches et al. (JACI 1997) found that only 45% of mite-monosensitized children treated with SCIT developed new sensitizations over follow-up, compared to 0% of controls. Purello-D'Ambrosio (Clin Exp Allergy 2001) found polysensitization developed in only 23.75% of SCIT-treated versus 68.03% of untreated monosensitized patients over 4 years. However, Di Bona's systematic review (Allergy 2017) concluded that when restricted to randomized trials, the evidence remains inconclusive — most positive findings come from non-randomized studies with selection bias risk. Most guideline bodies do not endorse prevention of new sensitizations as an established indication, though the PAT study's asthma-prevention findings (Jacobsen 2007) are broadly accepted.

Desensitization and tolerance are distinct immunological states that AIT can produce, with different practical implications. Desensitization means the patient's reaction threshold has been raised — they can now tolerate allergen doses they previously could not, but only as long as they continue regular immunotherapy. If treatment stops, the threshold drops back. Tolerance means the immune system has durably accepted the allergen as non-threatening, maintaining non-reactivity even after treatment is stopped. Environmental AIT (shots or drops for pollen, dust mites, pet dander) aims to achieve tolerance — and the evidence from Durham (NEJM 1999) and Eng (Allergy 2006) confirms that 3-5 years of treatment can produce tolerance lasting 3-12 years off treatment. Oral immunotherapy for peanut allergy (OIT/Palforzia), by contrast, typically produces desensitization rather than tolerance — patients must continue daily maintenance dosing to retain the protective threshold.

The first immune changes detectable after starting allergy immunotherapy occur within hours. Novak and colleagues (JACI 2012) documented upregulation of histamine receptor 2 on basophils within 6 hours of the first venom immunotherapy buildup injections, suppressing mast cell degranulation. Within 2 to 4 weeks, allergen-specific FOXP3+ regulatory T cells and IL-10-producing Tr1 cells become detectable in blood. IgG4 blocking antibodies begin a measurable rise at 1 to 3 months, reaching 10-100-fold increases by 3 to 12 months. Clinically, many patients notice symptom improvement within the first pollen season — often after 3 to 6 months — though the disease-modifying benefit that persists post-treatment requires 3 or more years to fully consolidate.

Allergy immunotherapy meaningfully reduces allergic asthma symptoms and medication burden, though it produces little consistent improvement in lung function measurements like FEV1. The Abramson Cochrane review (2010, 88 RCTs) found a symptom SMD of -0.59 and a number needed to treat of 3 to prevent one asthma symptom deterioration. Evidence is strongest for house dust mite-driven asthma in monosensitized patients — HDM SCIT has shown FEV1 improvements of up to 5.37% predicted in this subgroup (Zheng, Front Pediatr 2023). AIT also reduces the risk of asthma developing in children with allergic rhinitis: the PAT study (Jacobsen 2007) found only 25% of SCIT-treated children developed asthma versus 45% of controls at 10-year follow-up. However, severe or uncontrolled asthma (FEV1 below 70% predicted) is a contraindication to starting immunotherapy injections.